Physician profile
Amjad Ali
NPI 1598739617
$823.53
in general payments reported to CMS, 2019-2025
13 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.91 · 2020: $159 · 2021: $123 · 2022: $166 · 2023: $160 · 2024: $15.42 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $382.27 | 2020-2025 | Camzyos |
| Melinta Therapeutics, LLC | $67.39 | 2019-2023 | Kimyrsa |
| Merck Sharp & Dohme LLC | $64.33 | 2020 | |
| Abbvie INC. | $56.37 | 2021 | |
| Abbott Laboratories | $45.89 | 2021 | |
| Novartis Pharmaceuticals Corporation | $39.57 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $31.06 | 2020-2022 | |
| Pfizer INC. | $30.37 | 2024-2025 | |
| Gilead Sciences, INC. | $27.36 | 2022 | |
| Greenwich Biosciences, INC. | $25.72 | 2020 | |
| Saol Therapeutics INC. | $18.26 | 2019 | |
| Aquestive Therapeutics, INC. | $17.68 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.